- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06771115
Estudio de fase 2a controlado con placebo de VTX3232 solo o en combinación con semaglutida en la obesidad
Un estudio de fase 2a, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinamia de VTX3232 solo o en combinación con semaglutida en participantes con obesidad
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35235
- 840005
-
-
California
-
Lake Forest, California, Estados Unidos, 92630
- 840003
-
Long Beach, California, Estados Unidos, 90815
- 840011
-
-
Florida
-
Largo, Florida, Estados Unidos, 33761
- 840001
-
Ocoee, Florida, Estados Unidos, 34761
- 840012
-
Port Orange, Florida, Estados Unidos, 32127
- 840016
-
-
Kansas
-
Newton, Kansas, Estados Unidos, 67114
- 840014
-
-
Louisiana
-
Marrero, Louisiana, Estados Unidos, 70072
- 840015
-
Marrero, Louisiana, Estados Unidos, 70072
- 840017
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- 840002
-
Dallas, Texas, Estados Unidos, 75230
- 840006
-
San Antonio, Texas, Estados Unidos, 78229
- 840013
-
San Antonio, Texas, Estados Unidos, 78229
- 840018
-
Waco, Texas, Estados Unidos, 76710
- 840010
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Participants are male or female ≥ 18 years up to ≤ 80 years of age.
- Ability to comply with study requirements.
- BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening.
- Stable body weight (± 5%) for at least 3 months prior to screening.
- hs-CRP ≥ 2 mg/L at screening.
- Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy.
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion Criteria:
-
Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity
-
Have any prior diagnosis of diabetes mellitus
-
Current participation (or within the last 3 months) in an organized weight reduction program.
-
History or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass [bariatric] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity.
-
Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.
-
Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study.
-
Receipt of the following medications:
- Any immunosuppressive biologic or targeted therapy within 90 days prior to Day 1.
- Use of anti-inflammatory medications within 30 days prior to Day 1
- Colchicine within 30 days prior to Day 1.
- Glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
Participants received placebo orally once daily for 12 weeks and were followed for 30 days after the last dose. |
Placebo |
|
Experimental: VTX3232 30 mg
Participants received VTX3232 30 milligrams (mg) orally once daily for 12 weeks and were followed for 30 days after the last dose. |
VTX3232 30 mg |
|
Comparador activo: Placebo + Semaglutide
Participants received placebo orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose. |
Placebo in combination with semaglutide |
|
Experimental: VTX3232 30 mg + Semaglutide
Participants received VTX3232 30 mg orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose. |
VTX3232 30 mg in combination with semaglutide |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: From the first dose of study treatment to Week 16
|
A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment. |
From the first dose of study treatment to Week 16
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level
Periodo de tiempo: From baseline to Week 12
|
From baseline to Week 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Snehal Naik, PhD, Zomagen Biosciences Ltd.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- VTX3232-204
- J7V-MC-EOBA (Otro identificador: Eli Lilly and Company)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .